Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients The introduction of a new measure

作者：Driessen C M L; de Kleine Bolt K M E; Vingerhoets A J J M; Mols F^*; Vreugdenhil G

来源：Supportive Care in Cancer, 2012, 20(4): 877-881.

DOI：10.1007/s00520-011-1336-0

• Cancer
• Oncology
• Neurotoxicity
• Chemotherapy
• Quality of life

To investigate the impact of chemotherapy-induced neurotoxicity on daily activities and quality of life (QoL) of cancer patients. %26lt;br%26gt;QoL of all patients visiting the oncological outpatient ward of the Maxima Medical Centre in the Netherlands from October 2006 until March 2007 treated with taxanes, vinca-alkaloids and/or platinum compounds (n = 88) was compared with the QoL of patients that did not receive these treatments yet (n = 43). Patient-reported neuropathy symptoms were evaluated with the newly developed Chemotherapy Induced Neurotoxicity Questionnaire (CINQ) and the Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group/Neurotoxicity (FACT/GOG-Ntx) questionnaire. %26lt;br%26gt;Patients treated with chemotherapy reported significantly more complaints of neuropathy (p %26lt; 0.001) and more paresthesias and dysesthesias in the upper (p %26lt; 0.001; p %26lt; 0.01) and lower extremities (p %26lt; 0.001) compared to those not treated with chemotherapy. They additionally experienced problems with fine motor e.g., getting (un)dressed, writing, and picking up small objects). Moreover, cold-induced paresthesias were frequently reported. Overall, patients indicated that their neuropathy had a negative effect on QoL. %26lt;br%26gt;The newly developed CINQ and the FACT/GOG-Ntx results suggest a considerable negative impact of patient-reported neuropathy symptoms on daily activities and QoL in cancer patients treated with chemotherapy. However, further validation of the CINQ is needed.

• 出版日期2012-4